28 Ces Urol 2024; 28(1): 22–29 PŘEHLEDOVÉ ČLÁNKY 10. Ghazi A, Erturk E, Joseph J V. Modifications to facilitate extraperitoneal robot-assisted radical prosta‑ tectomy post kidney transplant JSLS J Soc Laparoendosc Surg 2012; 16(2): 314–19 11. Mladá J, Vacková P. Kontrastní látky s obsahem gadolinia a nefrogenní systémová fibróza Urol praxi 2011; 12(3): 189–90 12. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent Invest Radiol 2008; 43(2): 141–44 13. Townsend RR, Cohen DL, Katholi R, et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency Am J Kidney Dis 2000; 36(6): 1207–12 14. Chadban SJ, Ahn C, Axelrod DA, et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation Transplantation 2020; 104(4S1 Suppl 1): S11–103 15. Jurdi A Al, Gilligan H, Cohen-Bucay A. Delaying Kidney Transplantation in Patients With Prostate Cancer: Is It Warranted? Kidney Med 2021; 3(6): 893–95 16. EAU Guidelines. Edn presented at the EAU Annual Congress Milan 2021 ISBN 978-94-92671-13-4 17. Abramowicz D, Cochat P, Claas F, et al. Guideline Nephrol Dial Transplant 2013; 28(suppl_2): ii1–71 18. Al-Adra DP, Hammel L, Roberts J, et al. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement Am J Transplant 2021; 21(2): 460–74 19. Hsieh TC, Xu W, Chiao JW. Growth regulation and cellular changes during differentiation of human pro‑ static cancer LNCaP cells as induced by T lymphocyte-conditioned medium Exp Cell Res 1995; 218(1): 137–43 20. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 1999; 397(6719): 530–34 21. Pollard M. Enhancement of metastasis of prostate adenocarcinoma cells by immune-suppressive cyclosporine A Cancer Lett 1997; 111(1–2): 221–24 22. Robson R, Cecka JM, Opelz G, et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil Am J Transplant 2005; 5(12): 2954–60 23. David KM, Morris JA, Steffen BJ, et al. Mycophenolate mofetil vs azathioprine is associated with dec‑ reased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes Clin Transplant 2005; 19(2): 279–85 24. Kleinclauss F, Gigante M, Neuzillet Y, et al. Prostate cancer in renal transplant recipients Nephrol Dial Transplant 2008; 23(7): 2374–80 25. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts Cancer Res 2005; 65(7): 2825–31 26. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells Cancer Res 2006; 66(20): 10040–47 27. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapa‑ mycin inhibitors is associated with a reduced incidence of de novo malignancies Transplantation 2005; 80(7): 883–89 28. Kauffman HM, Cherikh WS, McBride MA, et al. Post-transplant de novo malignancies in renal transplant recipients: the past and present Transpl Int 2006; 19(8): 607–20 29. Sheil AG. Patterns of malignancies following renal transplantation Transplant Proc 1999; 31(1–2): 1263–65 30. Schaeffer EM, Srinivas S, Adra N, et al. NCCN Clinical Practice Guidelines in Oncology Prostate Cancer 2023;21(10):1067–1096 31. Polcari AJ, Allen JC, Nunez-Nateras R, et al. Multicenter Experience With Robot-assisted Radical Pro‑ statectomy in Renal Transplant Recipients Urology 2012; 80(6): 1267–72
RkJQdWJsaXNoZXIy NDA4Mjc=